Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library

Microbiology and Immunology

Volumn 52, Issue 3, 2008, Pages 162-170

  Shibuya, Tadamasa ^a   Yamashiro, Tetsu ^b   Masaike, Yuka ^c   Ohuchi, Masanobu ^d   Uechi, Gen Ichiro ^b   Nishizono, Akira ^a  

^a OITA UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

H3N2 subtype; Human monoclonal antibody; Influenza A; Phage display

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; INFLUENZA VACCINE; RNA; EPITOPE; PEPTIDE LIBRARY; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY LIBRARY; ARTICLE; BACTERIUM TRANSFORMATION; BIOPANNING; CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; LYMPHOCYTE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PROTEIN PURIFICATION; VIRUS STRAIN; EPITOPE MAPPING; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; SERODIAGNOSIS; VIRUS CULTURE;

INFLUENZA A VIRUS;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PLAQUE ASSAY;

EID: 51449103253     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00025.x     Document Type: Article

References (35)

1. Fouchier R.A., Munster V.,Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., Osterhaus A.D. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-22.
2. Palese P. (2004) Influenza: old and new threats. Nat Med 10: S82-7.
3. Richman D.D.,Whitley R.J., Hayden F.G. (2002) Clinical virology. In: Hayden F.G., Palese P., eds. Influenza Virus, 2nd edn. Washington, DC: ASM Press, pp. 891-920.
4. Simonsen L., Clarke M.J.,Williamson G.D., Stroup D.F., Arden N.H., Schonberger L.B. (1997) The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87: 1944-50.
5. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y. (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353: 1374-85.
6. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F.,Webster R.G. (1998) Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351: 472-7.
7. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., Pham T.S., Vo C.D., Le T.Q., Ngo T.T., Dao B.K., Le P.P., Nguyen T.T., Hoang T.L., Cao V.T., Le T.G., Nguyen D.T., Le H.N., Nguyen K.T., Le H.S., Le V.T., Christiane D., Tran T.T., Menno de J., Schultsz C., Cheng P., LimW., Horby P., Farrar J. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-88.
8. Yuen K.Y., Chan P.K., Peiris M., Tsang D.N., Que T.L., Shortridge K.F., Cheung P.T., ToW.K., Ho E.T., Sung R., Cheng A.F. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351: 467-71.
9. Buxton Bridges C., Katz J.M., SetoW.H., Chan P.K., Tsang D., Ho W., Mak K.H., LimW., Tam J.S., Clarke M.,Williams S.G., Mounts A.W., Bresee J.S., Conn L.A., Rowe T., Hu-Primmer J., Abernathy R.A., Lu X., Cox N.J., Fukuda K. (2000) Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 181: 344-8.
10. Katz J.M., LimW., Bridges C.B., Rowe T., Hu-Primmer J., Lu X., Abernathy R.A., Clarke M., Conn L., Kwong H., Lee M., Au G., Ho Y.Y., Mak K.H., Cox N.J., Fukuda K. (1999) Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 180: 1763-70.
11. WillatsW.G. (2002) Phage display: practicalities and prospects. Plant Mol Biol 50: 837-54.
12. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-7.
13. Maruyama T., Rodriguez L.L., Jahrling P.B., Sanchez A., Khan A.S., Nichol S.T., Peters C.J., Parren P.W., Burton D.R. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73: 6024-30.
14. Men R., Yamashiro T., Goncalvez A.P.,Wernly C., Schofield D.J., Emerson S.U., Purcell R.H., Lai C.J. (2004) Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78: 4665-74.
15. Couch R.B., Kasel J.A. (1983) Immunity to influenza in man. Annu Rev Microbiol 37: 529-49.
16. GerhardW. (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260: 171-90.
17. Asaoka N., Tanaka Y., Sakai T., Fujii Y., Ohuchi R., Ohuchi M. (2006) Low growth ability of recent influenza clinical isolates in MDCK cells is due to their low receptor binding affinities. Microbes Infect 8: 511-9.
18. Williamson R.A., Burioni R., Sanna P.P., Partridge L.J., Barbas C.F. 3rd, Burton D.R. (1993) Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci USA 90: 4141-5.
19. Ando T., Yamashiro T., Takita-Sonoda Y., Mannen K., Nishizono A. (2005) Construction of human Fab library and isolation of monoclonalFab with rabies virus-neutralizing ability. Microbiol Immunol 49: 311-22.
20. Glamann J., Burton D.R., Parren P.W., Ditzel H.J., Kent K.A., Arnold C., Montefiori D., Hirsch V.M. (1998) Simian immunodeficiency virus (SIV) envelope-specificFab with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infectedmacaque. J Virol 72: 585-92.
21. Arakawa M., Yamashiro T., Uechi G., Tadano M., Nishizono A. (2007) Construction of Human Fab (gamma1/kappa) Library and Identification of Human Monoclonal Fab Possessing Neutralizing Potency against Japanese Encephalitis Virus. Microbiol Immunol 51: 617-25.
22. Lin C.W.,Wu S.C. (2003) A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol 77: 2600-6.
23. Webstar R., Cox N., Stohr K. (2002) Identification of influenza isolates by hemagglutinjation inhibiton. In:Webstar R., Cox N., Stohr, K., eds. WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva:World Health Organization, pp. 28-36.
24. Edwards M.J., Dimmock N.J. (2001) Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol 75: 10208-18.
25. Schofield D.J., Stephenson J.R., Dimmock N.J. (1997) Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. The Journal of General Virology 78(Pt 10): 2431-9.
26. Skehel J.J.,Wiley D.C. (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531-69.
27. Underwood P.A. (1982) Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies. The Journal of General Virology 62(Pt 1): 153-69.
28. Wiley D.C.,Wilson I.A., Skehel J.J. (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-8.
29. Bakker A.B., MarissenW.E., Kramer R.A., Rice A.B.,WeldonW.C., Niezgoda M., Hanlon C.A., Thijsse S., Backus H.H., de Kruif J., Dietzschold B., Rupprecht C.E., Goudsmit J. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79: 9062-8.
30. Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L. (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of Internal Medicine 145: 599-609.
31. Hanson B.J., Boon A.C., Lim A.P.,Webb A., Ooi E.E.,Webby R.J. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research 7: 126.
32. Simmons C.P., Bernasconi N.L., Suguitan A.L., Mills K.,Ward J.M., Chau N.V., Hien T.T., Sallusto F., Ha do Q., Farrar J., de Jong M.D., Lanzavecchia A., Subbarao K. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 4: e178.
33. 2 in mice. Respiratory Research 7: 43.
34. 2 fragments. Clin Exp Immunol 111: 583-7.
35. Caton A.J., Brownlee G.G., Yewdell J.W., GerhardW. (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-27.